Render Target: SSR
Render Timestamp: 2024-08-29T22:15:29.201Z
Commit: 419142f0105700b709b94a8ebde4734bae2c62a3
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

JARID1D (E4D4B) Rabbit mAb #78995

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H Mk
    SENSITIVITY Endogenous
    MW (kDa) 190
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    JARID1D (E4D4B) Rabbit mAb recognizes endogenous levels of total JARID1D protein.

    Species Reactivity:

    Human, Monkey

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human JARID1D protein.

    Background

    The methylation state of lysine residues in histone proteins is a major determinant for formation of active and inactive regions of the genome and is crucial for proper programming of the genome during development (1,2). Jumonji C (JmjC) domain-containing proteins represent the largest class of potential histone demethylase proteins (3). The JmjC domain can catalyze the demethylation of mono-, di-, and tri-methyl lysine residues via an oxidative reaction that requires iron and α-ketoglutarate (3). Based on homology, both humans and mice contain at least 30 such proteins, which can be divided into 7 separate families (3). The JARID (Jumonji/AT-rich interactive domain-containing protein) family contains four members: JARID1A (also RBP2 and RBBP2), JARID1B (also PLU-1), JARID1C (also SMCX), and JARID1D (also SMCY) (4). In addition to the JmJC domain, these proteins contain JmJN, BRIGHT, C5HC2 zinc-finger, and PHD domains, the latter of which binds to methylated histone H3 (Lys9) (4). All four JARID proteins demethylate di- and tri-methyl histone H3 Lys4; JARID1B also demethylates mono-methyl histone H3 Lys4 (5-7). JARID1A is a critical RB-interacting protein and is required for Polycomb-Repressive Complex 2 (PRC2)-mediated transcriptional repression during ES cell differentiation (8). A JARID1A-NUP98 gene fusion is associated with myeloid leukemia (9). JARID1B, which interacts with many proteins including c-Myc and HDAC4, may play a role in cell fate decisions by blocking terminal differentiation (10-12). JARID1B is overexpressed in many breast cancers and may act by repressing multiple tumor suppressor genes, including BRCA1 and HOXA5 (13,14). JARID1C has been found in a complex with HDAC1, HDAC2, G9a, and REST, which binds to and represses REST target genes in non-neuronal cells (7). JARID1C mutations are associated with X-linked mental retardation and epilepsy (15,16). JARID1D is uniquely localized to the Y chromosome, and functions as a tumor suppressor by repressing genes associated with cell invasiveness (17). JARID1D is frequently mutated in metastatic prostate tumors, and low JARID1D levels are associated with poor prognosis in prostate cancer patients (17).

    1. Kubicek, S. et al. (2006) Ernst Schering Res Found Workshop, 1-27.
    2. Lin, W. and Dent, S.Y. (2006) Curr Opin Genet Dev 16, 137-42.
    3. Klose, R.J. et al. (2006) Nat Rev Genet 7, 715-27.
    4. Benevolenskaya, E.V. (2007) Biochem Cell Biol 85, 435-43.
    5. Christensen, J. et al. (2007) Cell 128, 1063-76.
    6. Yamane, K. et al. (2007) Mol Cell 25, 801-12.
    7. Tahiliani, M. et al. (2007) Nature 447, 601-5.
    8. Pasini, D. et al. (2008) Genes Dev 22, 1345-55.
    9. van Zutven, L.J. et al. (2006) Genes Chromosomes Cancer 45, 437-46.
    10. Secombe, J. et al. (2007) Genes Dev 21, 537-51.
    11. Barrett, A. et al. (2007) Int J Cancer 121, 265-75.
    12. Dey, B.K. et al. (2008) Mol Cell Biol 28, 5312-27.
    13. Barrett, A. et al. (2002) Int J Cancer 101, 581-8.
    14. Lu, P.J. et al. (1999) J Biol Chem 274, 15633-45.
    15. Tzschach, A. et al. (2006) Hum Mutat 27, 389.
    16. Jensen, L.R. et al. (2005) Am J Hum Genet 76, 227-36.
    17. Li, N. et al. (2016) Cancer Res 76, 831-43.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.